CD44v6, as a tumor marker in the CD44 family, forms a trimeric complex with MET and HGF to promote MET activation and activate three downstream pathways: RAS-MAPK activation, PI3K/Akt promotion, and MET transcription enhancement (Figure 3A) (42). Here, MET is linked to neoplasm.